NCT06600997尚未招募不适用
Parent Artery Reconstruction for Small Unruptured Cerebral Aneurusms Using Flow DiverTers: a Multicenter Randomized Trial(PARAT-MT)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 1,008
- 主要终点
- Major recurrence, any stroke or death
研究概览
简要总结
A prospective, multicenter, randomized controlled clinical trial with open-label treatment and blinded endpoint assessment.
详细描述
The PARAT-MT is to evaluate whether small unruptured cerebral aneurusm patients treated with FD superior to those treated with conventional endovascular therapy. It is a prospective, multicenter, randomized controlled clinical trial with open-label treatment and blinded endpoint assessment trial.
Primary Outcome Endpoint A composite endpoint of major recurrence, any stroke or death at one year post-surgery.
Second Outcome Endpoint
- All-cause mortality at 12 months post-surgery.
- Any stroke at 12 months post-surgery.
- Major recurrence rate at 12 months post-surgery.
- Transient ischemic attack (TIA) occurrence rate at 12 months post-surgery.
- Periprocedural (30-day) procedure-related complications rate.
- Ipsilateral stroke or neurologic death at 1 month and 12 months post-surgery
- Severe disability rate at 1 month and 12 months post-surgery (mRS > 2).
- Complete aneurysm occlusion rate at 12 months post-surgery (Raymond I).
- The rate of in-stent stenosis ≥50% at 12 months post-surgery.
- Incidence of hemorrhagic stroke at 12 months post-surgery.
- Technical success rate.
- Target parent artery retreatment rate at 12 months post-surgery.
- Target aneurysm retreatment rate at 12 months post-surgery.
- Surgical operation time.
- Radiation dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-75 years.
- •Previously unruptured saccular cerebral aneurysm arising from intradural segments of the internal carotid artery and intracranial segments of the vertebral artery.
- •Measuring ≤10mm in maximum diameter
- •Subjects capable of understanding the study's purpose, willing to participate, and have signed an informed consent form.
排除标准
- •Subjects with two or more multiple aneurysms requiring treatment within one year.
- •Subjects with arteriovenous malformations or moyamoya disease.
- •Subjects with ruptured, recurrent, or dissecting aneurysms.
- •Subjects with symptomatic cerebral stenosis >70%;
- •Subjects who have experienced a stroke (cerebral hemorrhage, cerebral infarction) within the past month.
- •Clinical condition is extremely poor with a modified Rankin score of ≥
- •Subjects planned for surgical/interventional procedures within three months.
- •Subjects deemed inappropriate for interventional treatment by the investigator (e.g., no suitable vascular access, excessively tortuous vessels, difficult stent delivery, etc.).
- •Subjects with severe comorbidities, unsuitable for anesthesia or endovascular surgery (e.g., major cardiac, pulmonary, hepatic, splenic, renal diseases, atrial fibrillation ,brain tumors, severe active infections, disseminated intravascular coagulation, history of severe mental illness).
- •Subjects unable to tolerate antiplatelet or anticoagulant therapy.
- •Subjects who has had or are likely to have a severe reaction to contrast media.
- •Subjects with a history of allergy to nickel-titanium, cobalt-chromium, or platinum-tungsten alloys.
- •Subjects who have participated in other drug or medical device clinical trials and have not reached the primary endpoint time limit.
- •Pregnant or breastfeeding women.
- •Subjects with an expected lifespan of less than 12 months.
- •Subjects deemed by the investigator to have poor compliance, unable to complete the study as required.
结局指标
主要结局
Major recurrence, any stroke or death
时间窗: At 1 year post-surgery
A composite endpoint of major recurrence, any stroke or death
次要结局
- All-cause mortality(At 12 months post-surgery)
- Any stroke(At 12 months post-surgery)
- Major recurrence(At 12 months post-surgery)
- Transient ischemic attack (TIA)(At 12 months post-surgery)
- Procedure-related complications(Periprocedural (30 days))
- Ipsilateral stroke or neurologic death(At 1 month and 12 months post-surgery)
- Severe disability(At 1 month and 12 months post-surgery)
- Complete aneurysm occlusion(at 12 months post-surgery)
- The rate of in-stent stenosis ≥50%(At 12 months post-surgery)
- hemorrhagic stroke(at 12 months post-surgery)
- Technical success rate(24 hours after endovascular treatment)
- Target parent artery retreatment rate(At 12 months post-surgery)
- Target aneurysm retreatment rate(At 12 months post-surgery)
- Surgical operation time(during surgery)
- Radiation dose(during surgery)
研究者
相似试验
招募中
不适用
Complete Revascularization Versus Culprit Lesion Only PCI in NSTEMINon-ST-elevation Myocardial InfarctionMultivessel Coronary Artery DiseaseNCT05786131Leipzig Heart Science gGmbH3,390
已完成
不适用
Reconstruction Techniques and Vascular Approach After Laparoscopic Left Hemicolectomy and Rectum Low Anterior ResectionRectal TumorsColorectal CancerNCT02746224Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta64
已完成
不适用
The Comparative Effectiveness of Hybrid Revascularization (MIDCAB Then PCI) With DES Versus Multivessel DES PCI or CABGCoronary DiseaseHeart DiseasesCoronary Artery DiseaseMyocardial IschemiaNCT01699048Russian Academy of Medical Sciences150
暂停
不适用
Multicenter trial of elective revascularization in patients with diabetes mellitus and mild anginal complaints.NL-OMON20816* The Netherlands Heart Foundation (NHS)* The Netherlands Organisation for Health Research and Development (ZonMw)800
尚未招募
不适用
A Randomized Clinical Trial on Urgent Angioplasty for IntraCranial Atherosclerotic Stenosis-related Large-Vessel Occlusion After Mechanical ThrombectomyICAS - Intracranial AtherosclerosisStrokeAISNCT06702657Changhai Hospital612